

Date 28 July 2026
Your Ref
Our Ref 11589

Enquiries to Richard Mutch
Extension 35687
Direct Line 0131 465 5687
loth.freedomofinformation@nhs.scot
richard.mutch@nhs.scot

Dear

FREEDOM OF INFORMATION – TYPE 1 DIABETES

I write in response to your request for information in relation to Type 1 diabetes.

Question:

1. Do you provide autoantibody testing for diagnosis of Type 1 diabetes?

Answer:

Yes

Question:

2. If yes, please indicate which assays are available either onsite or via referral to another laboratory:
- a. GAD
 - b. IA-2
 - c. ZnT8
 - d. IAA

Answer:

a.	Yes - via referral
b.	Yes - via referral
c.	Yes - via referral
d.	Not available

Question:

3. Does your organisation receive requests for Type 1 diabetes autoantibody testing in individuals without clinically diagnosed diabetes (e.g. screening of at-risk relatives or other asymptomatic individuals)?
- ☐ Yes
 - ☐ No
 - ☐ Unknown

Answer:

Unknown

Question:

4. Please provide the number of unique patients tested clinically for the following autoantibodies during:

- a. Calendar year 2025
- b. January–March 2026

Please exclude research-only testing where identifiable.

Please provide separate figures for:

- c. onsite testing
- d. outsourced/referred testing

If exact patient numbers are not available, please provide the closest available measure (e.g. **request numbers** or assay volumes) and specify the metric used. Answer table:

Answer:

a.	Not readily available
b.	Not readily available
c.	None
d.	All

		Patients Tested Onsite	Outside Lab
2025 (Calendar Year)	GAD only	None	None
	Combination of any of GAD, IA-2 and/or ZnT8	None	Triple tested only - 1522
	IAA only (if available)	None	Not available
1 st quarter 2026 (January – March)	GAD only	None	None
	Combination of any of GAD, IA-2 and/or ZnT8	None	Triple test - 172
	IAA only (if available)	None	Not available

Question:

5. If an external laboratory is used, please provide:

- a. laboratory/provider name
- b. location

Answer:

a.	Blood Sciences Department - Immunology at Royal Devon & Exeter NHS Foundation Trust
b.	Wonford Hospital

Question:

6. If readily available, please provide the number of unique patients in 2025 and Jan–Mar 2026 who tested positive for:

- a. one autoantibody
- b. two or more autoantibodies
- c. Please exclude research-only testing where possible

Answer:

a.	Not readily available
b.	Not readily available
c.	Not readily available

Question:

7. Of the unique patients who tested positive, how many were referred through an early stage/asymptomatic screening programme?

Answer:

Not readily available

Question:

8. Please provide the average turnaround time over the last 12 months for Type 1 diabetes autoantibody testing:
- a. onsite testing -
 - b. referred testing (if applicable) -

Answer:

a.	Not applicable
b.	24 days

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at www.itspublicknowledge.info/Appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhsllothian.scot/FOI/Pages/default.aspx>

Yours sincerely

ALISON MACDONALD
Executive Director, Nursing
Cc: Chief Executive